Pre-order Enquiry
Request Free Sample
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017
SKU ID : GMD-11218082 | Publishing Date : 22-Aug-2017 | No. of pages : 120
Detailed TOC of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017
Table of ContentsTable of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 6
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 22
3SBio Inc 22
Amgen Inc 22
arGEN-X BV 23
Biogen Inc 23
Boehringer Ingelheim GmbH 24
Bristol-Myers Squibb Company 24
CSL Ltd 25
Dova Pharmaceuticals Inc 25
Enzene Biosciences Ltd 26
Genosco Inc 26
GlaxoSmithKline Plc 27
Hansa Medical AB 27
Immunomedics Inc 28
Intas Pharmaceuticals Ltd 28
Jiangsu Hengrui Medicine Co Ltd 29
Momenta Pharmaceuticals Inc 30
Novartis AG 31
Pfizer Inc 32
Pharmagenesis Inc 32
Protalex Inc 33
Rigel Pharmaceuticals Inc 33
UCB SA 34
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles 35
avatrombopag - Drug Profile 35
belimumab - Drug Profile 38
BI-655064 - Drug Profile 46
efgartigimod alfa - Drug Profile 48
eltrombopag olamine - Drug Profile 51
eltrombopag olamine - Drug Profile 58
fostamatinib disodium - Drug Profile 59
GL-2045 - Drug Profile 65
Hetrombopag Olamine - Drug Profile 67
KLM-465 - Drug Profile 68
letolizumab - Drug Profile 70
M-230 - Drug Profile 71
M-254 - Drug Profile 72
M-281 - Drug Profile 73
PBF-1650 - Drug Profile 74
PHN-013 - Drug Profile 75
PRTX-100 - Drug Profile 76
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 83
rituximab - Drug Profile 84
romiplostim - Drug Profile 91
romiplostim biosimilar - Drug Profile 95
romiplostim biosimilar - Drug Profile 96
rozanolixizumab - Drug Profile 97
SKIO-703 - Drug Profile 98
thrombopoietin - Drug Profile 100
veltuzumab - Drug Profile 101
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 105
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 106
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 107
Featured News & Press Releases 107
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118
List of Figures, Tables and Charts Available in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017
List of TablesNumber of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biogen Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by CSL Ltd, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Dova Pharmaceuticals Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Enzene Biosciences Ltd, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GlaxoSmithKline Plc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2017
Keyplayers in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017
3SBio IncAmgen Inc
arGEN-X BV
Biogen Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CSL Ltd
Dova Pharmaceuticals Inc
Enzene Biosciences Ltd
Genosco Inc
GlaxoSmithKline Plc
Hansa Medical AB
Immunomedics Inc
Intas Pharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Momenta Pharmaceuticals Inc
Novartis AG
Pfizer Inc
Pharmagenesis Inc
Protalex Inc
Rigel Pharmaceuticals Inc
UCB SA
Request Sample
Request Discount
